A Phase IV Prospective, Open Label, Randomized, Crossover Study Evaluating BOTOX Cosmetic for Injection and JUVEDERM Injectable Gel for the Treatment of Moderate to Severe Facial Wrinkles and Folds
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 156
- 试验地点
- 3
- 主要终点
- Efficacy
研究概览
简要总结
The purpose of this study is to see how well Juvederm Ultra XC or Juvederm Ultra Plus XC, and BOTOX Cosmetic, work compared to each other and when used together for the cosmetic treatment of age-associated wrinkles and folds of the face.
详细描述
-
Compounds:
-
BOTOX Cosmetic (onabotulinumtoxinA) for Injection
-
JUVEDERM Ultra XC and JUVEDERM Ultra Plus XC Injectable Gel
-
The objectives of this study are:
-
To assess physician assessment of efficacy and incremental benefit following BOTOX Cosmetic and Juvederm for the treatment of moderate to severe facial wrinkles and folds;
-
To assess patient perceptions of treatment outcomes and incremental benefit following BOTOX Cosmetic and Juvederm for the treatment of moderate to severe facial wrinkles and folds.
-
Investigator and study sites:
-
multicenter study
-
5 Sites: 2 in US, 2 in Canada, 1 in EU
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult females or males, aged 25 to 65 years;
- •Subjects must be seeking treatment with either BOTOX® or JUVÉDERM injections;
- •Subjects must have one or more moderate to severe hyperfunctional facial lines of the upper face (i.e., glabellar lines, lateral canthal lines (crow's feet) or horizontal forehead lines) or moderate to severe nasolabial folds based on the physician observer assessment (0-3 scale);
- •Women must either be of non-childbearing potential (i.e., surgically sterilized or post-menopausal) or if of childbearing potential, must not be pregnant (as documented by a negative urine pregnancy test at the baseline examination) or lactating and must be practicing a medically acceptable method of birth control;
- •Subjects must be willing and able to provide written informed consent;
- •Subjects must be willing and able to follow the procedures outlined in this protocol.
排除标准
- •Female subjects who are pregnant (positive urine pregnancy test) or who have an infant they are breast-feeding or who are of childbearing potential and not practicing a reliable method of birth control;
- •Previous botulinum toxin or semipermanent injectable filler therapy within the past year or any prior history of permanent filler therapy injection;
- •Prior cosmetic procedures (i.e., liposuction, etc.) or visible scars that may affect evaluation of response and/or quality of photography;
- •Known allergy or sensitivity to any of the study medication or their components;
- •Known severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies;
- •Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis or any other disease that might interfere with neuromuscular function;
- •Concurrent use of aminoglycoside antibiotics that interfere with neuromuscular function;
- •Subjects with profound atrophy or excessive weakness of the muscles in the target area(s) of BOTOX injection;
- •Subjects with an infection at an injection site or systemic infection (in this case, postpone study entry until one week following recovery);
- •Concurrent participation in an investigational drug or device study or participation within 30 days of study start;
- •Subjects are not to undergo any additional cosmetic procedures during the study period;
- •Subjects are not to change use of any facial products up to 6 months prior to enrollment and during study period;
- •Subjects with a history of poor cooperation, non-compliance with medical treatment, or unreliability.
研究组 & 干预措施
Botox Cosmetic
onabotulinumtoxinA for injection
干预措施: onabotulinumtoxinA (Drug)
JUVÉDERM
JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
干预措施: JUVÉDERM (Drug)
结局指标
主要结局
Efficacy
时间窗: Week 4, 8, 12, 24
Assessments at Visits 3,5,6+7 (weeks 4,8,12,24) include: -Physician Global Aesthetic Improvement Scale (PGAIS). Ratings include no change, improved, much improved, very much improved. Number of subjects with improvement score for the 5 point PGAIS from baseline to Visit 7. -Objective Observer Global Aesthetic Improvement Scale Number of subjects with improvement score for the from baseline to Visit 7. Ratings include no change, some improvement, definite improvement, substantial improvement, and complete improvement.
次要结局
未报告次要终点
研究者
AboutSkin Dermatology
Joel L. Cohen, MD
AboutSkin Dermatology and DermSurgery, PC